03 August 2018
Visiongain’s new report Global Pharma Contract Sales Market 2018-2028 Contract Detailing, Contract Non-Personal Promotion, Medical Education Services, Sample Management Services, Teledetailing Services, Edetailing Services indicates that the global pharma contract sales market will see $9.48bn in spending in 2023.
The global pharma contract sales market is expected to grow at a CAGR of 9.6% in the first half of the forecast period. The market is expected to grow at a CAGR of 7.9% from 2017-2028. The market is estimated at $5.48bn in 2017 and $9.48bn in 2023.
The lead analyst of the report said: “Pharma companies will increasingly look to outsource field sales to CSOs, for a wide range of reasons including for promotion for mature products with smaller marketing budgets, for product launches for smaller pharma companies, and for expertise in reaching emerging markets.
Demand for MSLs and clinical education teams has risen rapidly in recent years, driven by the launch of complex, specialty medicines for chronic diseases, as well as by increased awareness of treatment options, and choice, among patients and doctors. The rising trend in outsourcing across the whole pharma sector will benefit the contract sales market in this 10-year forecast period, as will challenges in market access, complex drug development and the increasing influence of the payer in prescribing decisions.”
The 238-page report contains 88 tables and 64 figures that add visual analysis in order to explain the developing trends within the Global Pharma Contract Sales Market.
Visiongain provides revenue forecasts for the period 2018-2028 as well as qualitative analyses for the leading segments: Contract detailing (personal promotion/field sales), Contract non-personal promotion, with further sub-forecasting for teledetailing, eDetailing and others, Medical education services and Sample management services
This report also breaks down the revenue forecast for pharma contract sales market by therapeutic segments: Cardiovascular disease, Metabolic disorders, Cancer treatment and Other.
The 238-page report offers market forecasts for the US, Germany, UK, France, Italy, Spain, China, Japan, India, Russia, Brazil and Rest of the World. Moreover, our work discusses the leading companies in pharma contract sales.
The report Global Pharma Contract Sales Market 2018-2028 Contract Detailing, Contract Non-Personal Promotion, Medical Education Services, Sample Management Services, Teledetailing Services, Edetailing Services will be of value to anyone who wants to better understand the pharma contract sales market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the pharma contract sales market.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global stem cell technologies and applications market was valued at US$9,247 million in 2021 and is projected to grow at a CAGR of 8.9% during the forecast period 2022-2032.
01 December 2022
The biosimilars and follow-on biologics market is valued at US$19,668.3 million in 2022 and is projected to grow at a CAGR of 31.14% during the forecast period 2023-2033.
01 December 2022
The Medical Imaging market was valued at US$38.6 billion in 2021 and is projected to grow at a CAGR of 5.46% during the forecast period 2022-2032.
30 November 2022
The global antibody drug conjugates market was valued at US$3,668 million in 2021 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.